2008
- 2008/04/30
- Start of clinical research of cancer immunotherapy using RetroNectin® expansion culture system at Tianjin Cancer Institute & Hospital, China [New!]
- 2008/01/22
- MolMed S.p.A., a strategic partner of Takara Bio in gene therapy, obtains a regulatory approval to start a Phase III trial of HSV-TK gene therapy for high risk acute leukemia in Italy
- 2008/01/09
- Takara Bio to enter into an M-CRADA with Dr. Rosenberg's group at NCI initiating pre-clinical studies of gene therapy using RetroNectin®-expansion culture system
